Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq

Executive Summary

• Cybin Inc. announced a voluntary transfer of its U.S. stock exchange listing from NYSE American to the Nasdaq Global Market.
• The company will simultaneously rebrand and change its name to Helus Pharma, effective January 5, 2026.
• Trading on NYSE American will cease at market close on January 4, 2026, with trading commencing on Nasdaq at market open on January 5, 2026.

Key Details

• Listing Transfer: Voluntary move from NYSE American LLC to Nasdaq Global Market.
• Trading Schedule:
  • Cease trading on NYSE American: Market close, January 4, 2026.
  • Commence trading on Nasdaq: Market open, January 5, 2026.
• Corporate Rebranding:
  • New Company Name: Helus Pharma (pronounced "Heal Us").
  • New Ticker Symbol: "HELP" (replacing "CYBN").
  • The new name and ticker will apply to both the U.S. listing (Nasdaq) and the Canadian listing (Cboe Canada).
• Management Commentary: Eric So, interim CEO, stated the move marks the next step in the evolution of Cybin into a global pharmaceutical company and thanked NYSE American for support over the last four years.
• Company Pipeline Context: The release notes Cybin's current development programs, including CYB003 (Phase 3 for major depressive disorder, FDA Breakthrough Therapy Designation) and CYB004 (Phase 2 for generalized anxiety disorder).

Notable Quotes

• “We are pleased to join the community of global pharmaceutical companies listed on Nasdaq and thank the NYSE American for supporting the company over the last four years since our initial listing,” said Eric So, interim chief executive officer of Cybin. “The transfer to Nasdaq marks the next step in the evolution of Cybin into a global pharmaceutical company.”